bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with intermediate-advanced huge hepatocellular carcinoma.

Trial Details

NCT ID
NCT06061276
Phase
NA
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • bTAE-HAIC
  • Lenvatinib
  • Camrelizumab
Locations (sample)
  • Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

  • Clinical diagnosis of HCC.
  • Age between 18 and 75 years;
  • The maximum tumor size ≥10 cm, and the total tumor size ≥15 cm;
  • Intermediate-advanced huge HCC, advanced HCC with PVTT type I or type II or limited metastases (≤5).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →